Balhimycin
Also known as: A82846B analog, Amycolatopsis balhimycina antibiotic
Summary
Balhimycin is a naturally occurring glycopeptide antibiotic produced by Amycolatopsis balhimycina (formerly Amycolatopsis sp. DSM 5908). It is structurally closely related to vancomycin and serves as a key model compound for studying glycopeptide biosynthesis, structure-activity relationships, and mechanisms of resistance. It has not been developed as a clinical therapeutic agent.
Mechanism of Action
Inhibits bacterial cell wall biosynthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing transglycosylation and transpeptidation, leading to cell lysis and death.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Antibiotic resistance mechanism studyBasic ScienceModerate
- Glycopeptide biosynthesis elucidationBasic ScienceHigh
- Gram-positive bacterial infection researchAntimicrobial ResearchLow
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
- European UnionUnapprovedNo EMA approval; research compound only.
- United StatesUnapprovedNo FDA approval; research compound only.
- United KingdomUnapprovedNo MHRA approval; research compound only.
Balhimycin is not approved for clinical use in any jurisdiction. It is used exclusively as a research tool in academic and pharmaceutical settings to study glycopeptide antibiotic biosynthesis and resistance mechanisms.
Evidence & Sources
No sources recorded yet.